Catalio Capital Management, LP
Position in KALV — KalVista Pharmaceuticals, Inc.
CIK 1958125
NEW YORK, NY
Position in KALV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,586,471
New position
Shares Held
426,551
first reported quarter
Ownership
0.801%
of shares outstanding
% of Portfolio
1.79%
of 13F equity value
Holder Rank
#34
of 182 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalio Capital Management, LP holds $360,864,886 across 31 Biotechnology names. KALV ranks #15 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
560,308 | $47,021,047 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
432,014 | $32,081,359 | |
| 3 | ASND |
Ascendis Pharma A/S
|
129,111 | $29,531,559 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
1,043,670 | $24,380,131 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
409,031 | $21,564,114 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
1,037,984 | $19,617,897 | |
| 7 | SLNO |
Soleno Therapeutics Inc
|
577,808 | $19,345,011 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
850,797 | $17,824,197 |
All Filings in KALV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,586,471 | 426,551 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||